Home> Media Center>Updates

Shaoxing enterprise's innovation dream in capsules

ezhejiang.gov.cn| Updated: February 27, 2024 L M S

Meds 1.png

Dimdazenil Capsules developed by Zhejiang Jingxin Pharmaceutical Co. [Photo from Zhejiang Jingxin Pharmaceutical Co]

Zhejiang Jingxin Pharmaceutical Co, headquartered in Shaoxing, is racing to mass-produce a revolutionary type of miniature pills at the commencement of the Chinese New Year.

Efforts are underway at Workshop 202 to conduct on-site inspections for production registration, with a goal to achieve an impressive output of 100,000 capsules per day.

Dimdazenil, the capsule in focus, is a groundbreaking pharmaceutical. Recently endorsed by the National Medical Products Administration as a category 1 innovative medication, Dimdazenil represents a transformative solution.

Its imminent market launch in March will mark the end of a 16-year hiatus in new insomnia treatments in China. Supported by clinical trials demonstrating its superiority over conventional remedies, Dimdazenil embodies over a decade of pioneering efforts by Jingxin.

Meds 2.png

A Zhejiang Jingxin Pharmaceutical Co. laboratory [Photo from Zhejiang Jingxin Pharmaceutical Co]

In earlier years, Jingxin, like many of its counterparts, predominantly operated within the generics sector. However, Chairman Lyu Gang harbored ambitious aspirations. "Sustained progress necessitates innovation, even amid potential risks," asserts Lyu. Consequently, resources were redirected from generic ventures to foster innovation.

Despite facing setbacks, including the discontinuation of three projects in 2008, Jingxin embarked on a bold venture into neuropsychiatric drugs in 2009, notwithstanding daunting odds.

Following extensive negotiations, exclusive rights to Dimdazenil in China were secured in 2010. Tailoring the formulation to align with Chinese market preferences facilitated a substantial cost reduction of over 70 percent compared to the German prototype.

A significant milestone was reached on Dec 5, 2023, when official approval was granted by the National Medical Products Administration, sparking jubilation throughout the research facility.

Presently, Jingxin is spearheading over 10 innovative projects, with a majority being domestically conceived. Notably, seven projects are dedicated to addressing mental health concerns.

"While success cannot be guaranteed, perseverance remains a hallmark of our endeavors," Lyu noted.